Moderna announced its intention to offer $2 billion in convertible senior notes due in 2029, taking advantage of a significant jump in its stock price. This move aims to bolster the company's financial resources for ongoing research and development, particularly in its promising cancer vaccine program.
The stock surge, which saw Moderna's shares nearly triple at one point, was triggered by positive Phase 3 trial results for its individualized messenger RNA (mRNA) cancer vaccine, intismeran, developed in partnership with Merck & Co. While specific data from the trial for melanoma treatment were not disclosed, the announcement led to a massive increase in Moderna's market value, adding approximately $45 billion in a single day. This success has reinvigorated investor confidence in Moderna's pipeline beyond its COVID-19 vaccine.
Analysts have reacted positively to the news, with many revising their revenue projections for intismeran, with some, like William Blair analyst Myles Minter, predicting peak annual sales of $5.4 billion in melanoma alone for Moderna's 50-50 revenue split with Merck. The success of the melanoma vaccine has also increased optimism for Moderna's nine other ongoing trials in collaboration with Merck, including mid-stage results expected later this year or in 2027 for kidney and bladder cancers, and a late-stage trial for lung cancer. The convertible notes offering is seen as a strategic move to secure funding for these ambitious projects.
However, some analysts, such as Evercore ISI's Cory Kasimov and Leerink Partners analyst Daina Graybosch, have cautioned that the market's euphoric response might have set overly optimistic expectations. They noted that Moderna's new valuation "already prices in substantially more conviction than the data disclosed thus far supports" and that achieving the implied sales figures for intismeran could be challenging, especially given potential higher manufacturing costs compared to standard biologic drugs. Despite these caveats, the overall sentiment is that the trial results represent a "landmark moment" for Moderna and the field of mRNA cancer vaccines.
